Combatting Bacterial Resistance in Europe – Molecules Against Gram Negative Infections
COMBACTE-MAGNET is funded by the Innovative Medicines Initiative Joint Undertaking, cofunded by the European Commission FP7 Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA) and aims to determine more effective treatment strategies for intensive care unit (ICU) infections, particularly with Gram-negative bacteria.
Penta is a paediatric partner in the consortium and will be involved in the coordination of upcoming clinical studies among neonates in intensive care.
This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme and EFPIA companies in kind contribution. The amount of funding received in 2018 is 3.005,01 €.